A detailed history of Fox Run Management, L.L.C. transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Fox Run Management, L.L.C. holds 9,324 shares of CLDX stock, worth $234,312. This represents 0.07% of its overall portfolio holdings.

Number of Shares
9,324
Holding current value
$234,312
% of portfolio
0.07%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$32.06 - $44.56 $298,927 - $415,477
9,324 New
9,324 $316,000
Q1 2024

May 13, 2024

SELL
$35.22 - $51.88 $226,288 - $333,329
-6,425 Reduced 57.12%
4,824 $202,000
Q4 2023

Feb 13, 2024

BUY
$22.61 - $40.65 $254,339 - $457,271
11,249 New
11,249 $446,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.18B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Fox Run Management, L.L.C. Portfolio

Follow Fox Run Management, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Fox Run Management, L.L.C. with notifications on news.